Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
82 studies found for:    "Rubella"
Show Display Options
RSS Create an RSS feed from your search for:
"Rubella"
Need help? See RSS Feeds
Choose a feed type:
Show studies that were first received in the last 14 daysShow studies that were first received in the last 14 days
Show studies added or modified in the last 14 daysShow studies that were added or modified in the last 14 days
Rank Status Study
1 Completed Immunogenicity & Safety Study of GSK Biologicals' Combined Measles-mumps-rubella-varicella Vaccine 208136
Conditions: Rubella;   Varicella;   Mumps;   Measles;   Measles-Mumps-Rubella-Varicella Vaccine
Interventions: Biological: PriorixTM;   Biological: VarilrixTM;   Biological: GSK Biologicals' vaccine 208136
2 Completed Rubella Susceptibility in Multiparous Women
Conditions: Rubella;   Vaccine
Intervention:
3 Completed Immunogenicity & Safety Study of GSK Biologicals' 208136 Vaccine Formulated With New Measles and Rubella Working Seeds
Conditions: Measles;   Varicella;   Mumps;   Rubella
Interventions: Biological: Priorix-Tetra TM (combined measles-mumps-rubella-varicella vaccine);   Biological: GSK Biologicals' 208136, new formulation
4 Completed Study to Evaluate Safety and Imunogenicity of Double Viral Vaccine (MR) for Measles and Rubella
Conditions: Rubella;   Measles
Intervention: Biological: Double viral (MR) vaccine
5 Completed Comparative Study of the Immunogenicity of MMR (Measles, Mumps and Rubella) Single Dose and Multidose Presentations
Conditions: Measles;   Mumps;   Rubella
Intervention: Biological: MMR Vaccine
6 Completed
Has Results
Study of Japanese Encephalitis Chimeric Virus Vaccine Given With Measles-Mumps-Rubella Vaccine in Taiwanese Toddlers
Conditions: Japanese Encephalitis;   Measles;   Mumps;   Rubella
Intervention: Biological: Japanese encephalitis chimeric virus: Measles, mumps, and rubella live attenuated virus
7 Completed Immunogenicity and Safety of GSK Biologicals' Combined Measles-mumps-rubella Vaccine in Volunteers, Seven Years of Age and Older
Conditions: Rubella;   Mumps;   Measles
Interventions: Biological: Priorix®;   Biological: Merck's M-M-R®II, Measles, Mumps, and Rubella Virus Vaccine
8 Completed Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Combined Measles-mumps-rubella (MMR) Vaccine in Subjects Four to Six Years of Age
Conditions: Rubella;   Mumps;   Measles
Interventions: Biological: Priorix®;   Biological: Merck's M-M-R®II, Measles, Mumps, and Rubella Virus Vaccine (also known as M-M-R Vax Pro™);   Biological: Kinrix®;   Biological: Varivax®
9 Completed Immunogenicity and Safety of a Combined Vaccine to Prevent Measles, Mumps, Rubella and Chickenpox Diseases
Conditions: Measles;   Rubella;   Mumps;   Varicella
Intervention: Biological: Measles, Mumps, Rubella and Chickenpox (live vaccine)
10 Withdrawn Safety Study of Measles-Mumps-Rubella-Varicella (MMRV) Vaccine, Priorix-Tetra™ in Children Living in the Philippines
Conditions: Mumps;   Rubella;   Measles;   Varicella
Interventions: Biological: Priorix-Tetra™;   Other: Safety data collection
11 Completed Immunogenicity and Safety of Combined Vaccine to Prevent Measles, Mumps, Rubella and Chickenpox Diseases
Conditions: Mumps;   Rubella;   Measles;   Varicella
Intervention: Biological: Measles, Mumps, Rubella and Chickenpox (live vaccine)
12 Completed Immunogenicity and Safety of a Combined Vaccine to Prevent Measles, Mumps, Rubella and Chickenpox Diseases
Conditions: Mumps;   Varicella;   Rubella;   Measles
Intervention: Biological: Measles, Mumps, Rubella and Chickenpox (live vaccine)
13 Completed Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Combined Measles-mumps-rubella (MMR) Vaccine in Children in Their Second Year of Life
Conditions: Measles;   Mumps;   Rubella
Interventions: Biological: GSK Biologicals measles, mumps and rubella vaccine live (GSK 209762);   Biological: Merck & Co., Inc.'s M-M-R®II, combined measles-mumps-rubella virus vaccine live;   Biological: Varivax® (Merck & Co., Inc.);   Biological: Havrix®;   Biological: Prevnar 13® (Pfizer Inc.)
14 Completed Study of Immunogenicity, Reactogenicity and Safety of the Combined Measles, Mumps and Rubella Vaccine Produced by Bio-Manguinhos/Fiocruz in Children 12-15 Months of Age, Followed by Tetraviral Vaccine in Children 15-18 Months.
Conditions: Measles;   Mumps;   Rubella;   Varicella
Interventions: Biological: MMR Bio-Manguinhos;   Biological: MMR GlaxoSmithKline
15 Completed Safety and Immunogenicity Study of GlaxoSmithKline (GSK) Biologicals' Measles, Mumps and Rubella (MMR) Vaccine (209762) Compared to Merck & Co., Inc.'s MMR Vaccine in Healthy Children 12 to 15 Months of Age
Condition: Measles; Mumps; Rubella
Interventions: Biological: GSK Biologicals measles, mumps and rubella vaccine live (GSK 209762);   Biological: Merck & Co., Inc.'s M-M-R®II (also called M-M-R Vax Pro®), combined measles-mumps-rubella virus vaccine;   Biological: Varivax® (Merck & Co., Inc.);   Biological: Havrix®;   Biological: Prevnar 13® (Pfizer Inc.)
16 Completed Immunogenicity, Safety of Measles-mumps-rubella-varicella Vaccine (MeMuRu-OKA) Compared to Priorix™ Given With Varilrix™
Conditions: Rubella;   Varicella;   Mumps;   Measles
Interventions: Biological: MeMuRu-OKA (study vac);   Biological: MMR, Varicella vacc (control)
17 Completed Serological Study in Children 12 to 23 Months Vaccinated With MMR (Measles, Mumps and Rubella)
Conditions: Mumps;   Rubella;   Measles
Intervention: Biological: MMR (Mumps, Measles and Rubella)
18 Not yet recruiting Immunogenicity and Safety of Japanese Encephalitis Vaccine When Given With Measles-Mumps-Rubella Vaccine
Conditions: Encephalitis, Japanese;   Measles;   Mumps;   Rubella
Interventions: Biological: CD-JEV;   Biological: MMR
19 Completed Study to Evaluate Frozen Versus Refrigerated MMRV (Combined Measles, Mumps, Rubella, and Varicella) Investigational Vaccine (V221-016)
Conditions: Measles;   Mumps;   Rubella;   Varicella
Intervention: Biological: V221, measles, mumps, rubella and varicella (Oka/Merck) virus vaccine live / Duration of Treatment: 12 weeks
20 Completed Immunogenicity, Safety of Measles-Mumps-Rubella-Varicella Vaccine (MeMuRu-OKA) Compared to Priorix™ Given With Varilrix™
Conditions: Measles;   Mumps;   Rubella;   Varicella
Interventions: Biological: MeMuRu-OKA (study vacc);   Biological: MMR, Varicella vacc (control)

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Indicates status has not been verified in more than two years